{
    "doi": "https://doi.org/10.1182/blood.V118.21.5014.5014",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=2038",
    "start_url_page_num": 2038,
    "is_scraped": "1",
    "article_title": "Polymorphisms in Regulators of Xenobiotic Transport and Metabolism Genes NR1I2 and NR1I3 and Multiple Myeloma Risk: A Case-Control Study in the Context of IMMEnSE Consortium ",
    "article_date": "November 18, 2011",
    "session_type": "Molecular Pharmacology, Drug Resistance",
    "topics": [
        "genes",
        "metabolism",
        "multiple myeloma",
        "pregnane x receptor",
        "xenobiotics",
        "polymorphism",
        "transluminal attenuation gradient",
        "enzymes",
        "genotype determination",
        "membrane transport proteins"
    ],
    "author_names": [
        "Gabriele Buda, M.D., PhD",
        "Alessandro Martino, PhD",
        "Daniele Campa",
        "Juan Sainz",
        "Rui Manuel Vieira Reis",
        "Ramo\u0301n Garci\u0301a-Sanz",
        "Krzysztof Jamroziak",
        "Rafael Rios",
        "Manuel Jurado",
        "Zofia Szemraj-Rogucka",
        "Herlander Marques",
        "Victor Moreno",
        "Fabienne Lesueur",
        "Charles Dumontet, M. D., Ph. D.",
        "Federica Gemignani",
        "Stefano Landi",
        "Enrico Orciuolo",
        "Anna Maria Rossi",
        "Mario Petrini, MD",
        "Federico Canzian"
    ],
    "author_affiliations": [
        [
            "Section of Hematology, University of Pisa, Pisa, Italy, "
        ],
        [
            "Genomic Epidemiology Group, German Cancer Research Center DKFZ, Heidelberg, Germany, "
        ],
        [
            "Genomic Epidemiology Group, German Cancer Research Center DKFZ, Heidelberg, Germany, "
        ],
        [
            "Hematology department, Virgen de las Nieves University Hospital, granada, Spain, "
        ],
        [
            "Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, braga, Portugal, "
        ],
        [
            "Hospital Universitario de Salamanca, Salamanca, Spain, "
        ],
        [
            "Dept Hematol, Med Univ of Lodz, Lodz, Poland, "
        ],
        [
            "Hematology department, Virgen de las Nieves University Hospital, Granada, Spain, "
        ],
        [
            "Hospital Virgen de las Nieves, Spain, "
        ],
        [
            "Department of Hematology, Medical University of Lodz, Lodz, Poland, "
        ],
        [
            "Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, "
        ],
        [
            "IDIBELL- Catalan Institute of Oncology and University of Barcelona, Barcelona, Spain, "
        ],
        [
            "Genetic Cancer Susceptibility Group, International Agency for Research on Cancer (IARC), Lyon, France, "
        ],
        [
            "Laboratoire de Cytologie Analytique, INSERM UMR 1052/CNRS 5286, Lyon, France, "
        ],
        [
            "Department of Biology, Section of Genetics, University of Pisa, Pisa, Italy, "
        ],
        [
            "Department of Biology, Section of Genetics, University of Pisa, Pisa, Italy, "
        ],
        [
            "Section of Hematology, University of Pisa, Pisa, Italy, "
        ],
        [
            "Dept of Biology, University of Pisa, Pisa, Italy, "
        ],
        [
            "University of Pisa, Section of Hematology, Pisa, Italy"
        ],
        [
            "Genomic Epidemiology Group, German Cancer Research Center DKFZ, Heidelberg, Germany, "
        ]
    ],
    "first_author_latitude": "43.7167235",
    "first_author_longitude": "10.3988593",
    "abstract_text": "Abstract 5014 Exposure to toxic compounds and pesticides leads to an increased risk to develop Multiple Myeloma (MM). The metabolism and the excretion of xenobiotics are mediated by the enzymes and transporters acting in the detoxifying/elimination process. The nuclear receptors NR1I2 (or PXR ) and NR1I3 (or CAR ) act as xenosensor activating the detoxifying/elimination process in response to the intracellular levels of xenobiotics. It has been hypothesized that part of the individual variability in drug metabolism efficiency could be due to the genetic variations within these regulator genes affecting their expression and/or function. To investigate the impact of genetic variation within these genes on MM susceptibility, we selected and genotyped 10 tag Single Nucleotide Polymorphisms (SNPs) in the PXR gene and 7 tag SNPs in the CAR gene in 627 MM cases (320 males and 307 females) and 883 (459 males and 424 females) controls from different European populations. All the SNPs were in Hardy-Weinberg equilibrium (p>0.001), with the exception of the PXR SNP rs2461818 that was therefore excluded from the analysis. We found no association of any of the genotyped SNPs with MM risk. In the same way, haplotype distribution showed no differences between cases and controls. This was the first comprehensive investigation of genetic variation in xenobiotic regulators genes PXR and CAR in relation to MM risk and our data suggest that common variants in these genes have no impact in modifying MM risk. Table I. Genotype distribution of the PXR and CAR SNPs among MM cases and controls.  SNP (rs) . Cases (%) . Controls (%) . OR * . 95%C.I . . p-value . p-trend . PXR  C/C 429 (69.5) 623 (70.7) 1.00 Ref  0.423  rs10511395 A/C 160 (25.9) 228 (25.9) 1.02 0.81 \u2013 1.30 0.851   A/A 28 (4.6) 30 (3.4) 1.38 0.81 \u2013 2.35 0.232   PXR  C/C 452 (74.0) 656 (74.8) 1.00 Ref  0.451  rs1054190 C/T 137 (22.4) 200 (22.8) 1.00 0.78 \u2013 1.28 0.993   T/T 22 (3.6) 21 (2.4) 1.56 0.84 \u2013 2.88 0.155   PXR  C/C 412 (65.9) 591 (67.2) 1.00 Ref  0.819  rs11917714 C/T 190 (30.4) 250 (28.5) 1.07 0.85 \u2013 1.35 0.535   T/T 23 (3.7) 38 (4.3) 0.84 0.49 \u2013 1.44 0.536   PXR  C/C 223 (36.3) 296 (33.7) 1.00 Ref  0.126  rs12488820 C/T 289 (47.0) 407 (46.4) 0.93 0.74 \u2013 1.18 0.574   T/T 103 (16.7) 175 (19.9) 0.79 0.58 \u2013 1.06 0.119   PXR  G/G 430 (69.6) 593 (67.4) 1.00 Ref  0.807  rs13071341 A/G 166 (26.9) 269 (30.6) 0.85 0.67 \u2013 1.07 0.158   A/A 22 (3.5) 18 (2.0) 1.70 0.90 \u2013 3.22 0.102   PXR  A/A 352 (58.7) 516 (39.4) 1.00 Ref  0.981  rs3237359 A/G 209 (34.8) 291 (33.5) 1.04 0.83 \u2013 1.30 0.720   G/G 39 (6.5) 62 (7.1) 0.90 0.59 \u2013 1.37 0.619   PXR  C/C 255 (41.2) 383 (43.6) 1.00 Ref  0.815  rs13059232 C/T 299 (48.3) 390 (44.4) 1.16 0.93 \u2013 1.44 0.192   T/T 65 (10.5) 106 (12.0) 0.94 0.66 \u2013 1.33 0.711   PXR  A/A 300 (48.7) 437 (49.7) 1.00 Ref  0.258  rs3732357 A/G 240 (39.0) 361 (41.0) 0.94 0.75 \u2013 1.17 0.589   G/G 76 (12.3) 82 (9.3) 1.31 0.92 \u2013 1.85 0.130   PXR  T/T 328 (53.6) 463 (52.9) 1.00 Ref  0.424  rs1357459 C/T 249 (40.7) 345 (39.4) 1.02 0.82 \u2013 1.27 0.850   C/C 35 (5.7) 67 (7.7) 0.75 0.49 \u2013 1.17 0.206   CAR  A/A 218 (35.4) 335 (38.1) 1.00 Ref  0.571  rs3003596 A/G 296 (48.0) 393 (44.7) 1.16 0.93 \u2013 1.46 0.191   G/G 102 (16.6) 151 (17.2) 1.04 0.77 \u2013 1.41 0.799   CAR  G/G 264 (42.7) 371 (42.0) 1.00 Ref  0.642  rs3813627 G/T 276 (44.7) 392 (44.4) 0.98 0.79 \u2013 1.23 0.882   T/T 78 (12.6) 120 (13.6) 0.91 0.66 \u2013 1.26 0.581   CAR  A/A 441 (73.1) 635 (73.5) 1.00 Ref  0.911  rs11265571 A/T 147 (24.4) 207 (24.0) 1.01 0.79 \u2013 1.29 0.911   T/T 15 (2.5) 22 (2.5) 0.97 0.49 \u2013 1.89 0.921   CAR  T/T 404 (64.2) 575 (65.7) 1.00 Ref  0.836  rs2307418 G/T 193 (31.1) 268 (30.6) 1.02 0.81 \u2013 1.27 0.879   G/G 23 (3.7) 32 (3.7) 1.05 0.60 \u2013 1.83 0.863   CAR  C/C 348 (56.6) 508 (57.7) 1.00 Ref  0.527  rs2502805 C/T 220 (35.8) 313 (35.6) 1.05 0.84 \u2013 1.30 0.693   T/T 47 (7.6) 59 (6.7) 1.16 0.77 \u2013 1.74 0.484   CAR  A/A 245 (39.8) 346 (39.4) 1.00 Ref  0.770  rs4073054 A/C 291 (47.2) 412 (46.9) 0.98 0.78 \u2013 1.22 0.855   C/C 80 (13.0) 120 (13.7) 0.94 0.68 \u2013 1.31 0.720   CAR  C/C 360 (57.6) 524 (59.8) 1.00 Ref  0.391  rs4233368 A/C 225 (36.0) 302 (34.4) 1.09 0.88 \u2013 1.36 0.439   A/A 40 (6.4) 51 (5.8) 1.15 0.74 \u2013 1.78 0.538   SNP (rs) . Cases (%) . Controls (%) . OR * . 95%C.I . . p-value . p-trend . PXR  C/C 429 (69.5) 623 (70.7) 1.00 Ref  0.423  rs10511395 A/C 160 (25.9) 228 (25.9) 1.02 0.81 \u2013 1.30 0.851   A/A 28 (4.6) 30 (3.4) 1.38 0.81 \u2013 2.35 0.232   PXR  C/C 452 (74.0) 656 (74.8) 1.00 Ref  0.451  rs1054190 C/T 137 (22.4) 200 (22.8) 1.00 0.78 \u2013 1.28 0.993   T/T 22 (3.6) 21 (2.4) 1.56 0.84 \u2013 2.88 0.155   PXR  C/C 412 (65.9) 591 (67.2) 1.00 Ref  0.819  rs11917714 C/T 190 (30.4) 250 (28.5) 1.07 0.85 \u2013 1.35 0.535   T/T 23 (3.7) 38 (4.3) 0.84 0.49 \u2013 1.44 0.536   PXR  C/C 223 (36.3) 296 (33.7) 1.00 Ref  0.126  rs12488820 C/T 289 (47.0) 407 (46.4) 0.93 0.74 \u2013 1.18 0.574   T/T 103 (16.7) 175 (19.9) 0.79 0.58 \u2013 1.06 0.119   PXR  G/G 430 (69.6) 593 (67.4) 1.00 Ref  0.807  rs13071341 A/G 166 (26.9) 269 (30.6) 0.85 0.67 \u2013 1.07 0.158   A/A 22 (3.5) 18 (2.0) 1.70 0.90 \u2013 3.22 0.102   PXR  A/A 352 (58.7) 516 (39.4) 1.00 Ref  0.981  rs3237359 A/G 209 (34.8) 291 (33.5) 1.04 0.83 \u2013 1.30 0.720   G/G 39 (6.5) 62 (7.1) 0.90 0.59 \u2013 1.37 0.619   PXR  C/C 255 (41.2) 383 (43.6) 1.00 Ref  0.815  rs13059232 C/T 299 (48.3) 390 (44.4) 1.16 0.93 \u2013 1.44 0.192   T/T 65 (10.5) 106 (12.0) 0.94 0.66 \u2013 1.33 0.711   PXR  A/A 300 (48.7) 437 (49.7) 1.00 Ref  0.258  rs3732357 A/G 240 (39.0) 361 (41.0) 0.94 0.75 \u2013 1.17 0.589   G/G 76 (12.3) 82 (9.3) 1.31 0.92 \u2013 1.85 0.130   PXR  T/T 328 (53.6) 463 (52.9) 1.00 Ref  0.424  rs1357459 C/T 249 (40.7) 345 (39.4) 1.02 0.82 \u2013 1.27 0.850   C/C 35 (5.7) 67 (7.7) 0.75 0.49 \u2013 1.17 0.206   CAR  A/A 218 (35.4) 335 (38.1) 1.00 Ref  0.571  rs3003596 A/G 296 (48.0) 393 (44.7) 1.16 0.93 \u2013 1.46 0.191   G/G 102 (16.6) 151 (17.2) 1.04 0.77 \u2013 1.41 0.799   CAR  G/G 264 (42.7) 371 (42.0) 1.00 Ref  0.642  rs3813627 G/T 276 (44.7) 392 (44.4) 0.98 0.79 \u2013 1.23 0.882   T/T 78 (12.6) 120 (13.6) 0.91 0.66 \u2013 1.26 0.581   CAR  A/A 441 (73.1) 635 (73.5) 1.00 Ref  0.911  rs11265571 A/T 147 (24.4) 207 (24.0) 1.01 0.79 \u2013 1.29 0.911   T/T 15 (2.5) 22 (2.5) 0.97 0.49 \u2013 1.89 0.921   CAR  T/T 404 (64.2) 575 (65.7) 1.00 Ref  0.836  rs2307418 G/T 193 (31.1) 268 (30.6) 1.02 0.81 \u2013 1.27 0.879   G/G 23 (3.7) 32 (3.7) 1.05 0.60 \u2013 1.83 0.863   CAR  C/C 348 (56.6) 508 (57.7) 1.00 Ref  0.527  rs2502805 C/T 220 (35.8) 313 (35.6) 1.05 0.84 \u2013 1.30 0.693   T/T 47 (7.6) 59 (6.7) 1.16 0.77 \u2013 1.74 0.484   CAR  A/A 245 (39.8) 346 (39.4) 1.00 Ref  0.770  rs4073054 A/C 291 (47.2) 412 (46.9) 0.98 0.78 \u2013 1.22 0.855   C/C 80 (13.0) 120 (13.7) 0.94 0.68 \u2013 1.31 0.720   CAR  C/C 360 (57.6) 524 (59.8) 1.00 Ref  0.391  rs4233368 A/C 225 (36.0) 302 (34.4) 1.09 0.88 \u2013 1.36 0.439   A/A 40 (6.4) 51 (5.8) 1.15 0.74 \u2013 1.78 0.538   Genotype distribution among MM cases and controls in the overall population. * OR are adjusted for age, gender and region of origin. Differences in samples numbers are due to failures in genotyping. View Large Disclosures: No relevant conflicts of interest to declare."
}